

## Anti-Spike RBD (SARS-CoV-2/COVID-19) Neutralizing Antibody

CATALOG NUMBER: SCV2-RBD-200m, 100 µg

<b>Introduction</b>	The novel coronavirus (SARS-CoV-2), previously called 2019-nCoV, is a newly identified coronavirus causing the ongoing outbreak of atypical pneumonia in Wuhan China from late 2019.  The genome of SARS-CoV-2 has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain (RBD) of SARS-CoV-2 shares only 40% amino acid identity with other SARS-related coronaviruses.
<b>Applications</b>	Western blot (1:1,000-1:2,000) and ELISA (1:5,000-10,000), other applications suggested IF, IP, Neutralization Assay.
<b>Description</b>	Human monoclonal anti-spike RBD (SARS-CoV-2/COVID-19) neutralizing antibody
<b>Immunogen</b>	Recombinant SARS-CoV-2 spike RBD protein
<b>Specificity</b>	Reacts to SARS-CoV-2 Spike RBD and spike protein. Cross-reaction to RBD domain and spike from other coronavirus not tested.
<b>Purification</b>	Affinity chromatography
<b>Isotype</b>	Human IgG; Clone# BB6
<b>Storage</b>	Store at -20 °C; Stable for 6-months from the date of shipment when kept at 4 °C. Non-hazardous. No MSDS required.
<b>Concentration</b>	1 µg/µl in PBS, pH7.4




Figure 2. Pseudoviral particle (PP) infection assay challenged by neutralizing antibody (SCV2-RBD-200m). HEK293-ACE2 cells infected with SARS-CoV-2 pseudoviral particles (Cat# SCV2-PsV-614G) under various amount of neutralizing antibodies, with IC50 of 24.7 ng/ml.